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Neuroendocrine carcinomas of the bladder (small cell, large cell, typical and atypical carcinoids)
are rare and usually co exist with urothelial carcinoma. As in small cell carcinoma of the lung,
various paraneoplastic neurologic disorders can occur although they are even less frequent. Here
we report the case of a 63 year old man with small cell carcinoma of the urinary bladder and with
a paraneoplastic neurologic disorder.
& 2013 The Authors. Published by Elsevier Ltd. All rights reserved.The Authors. Published by Elsevi
.12.001
buted under the terms of the
mercial-ShareAlike License,
istribution, and reproduction
nal author and source are
Medical Oncology, University
Avenue, 45500,Greece.
.gr (G. Fotopoulos).1. Introduction
Neuroendocrine carcinomas can arise in almost all
epithelium-containing organs, most commonly encountered
in the respiratory and gastrointestinal tract. Among the
histological patterns of urinary bladder tumors, neuroendo-
crine tumors can also be found. Although rare, they can be
distinguished and differentiated as small cell carcinomas
(SCUC), large cell neuroendocrine carcinomas (LCNEC),
typical and atypical carcinoids. Since the ﬁrst report of a
case of SCUC by Cramer [1], the cumulative number
reported has risen signiﬁcantly. The estimated incidence is
roughly 500 new cases annually [2].er Ltd. All rights reserved.
Figure 1 Small cell tumor with patterneless pattern.
Figure 2 Tumor cells positive for synaptophysin.
Figure 3 Tumor cells positive for chromogranin.
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neurologic disorder (PND) in this setting. We know that the
most common PND encountered in SCLC is the Lambert–Eaton
myasthenic syndrome which affects 3% of patients. For other
solid tumors the incidence of PND is less than 1% [3].
The purpose of this review is to present a case of SCUC
with a PND.
2. Case report
A 63 year old man was referred to our institution with
recurrent episodes of painless haematuria over an one month
period. The patient had a history of diabetes mellitus,
hypertension and hyperthyroidism. He reported moderate
alcohol consumption and was a smoker of 80 pack years.
A cystoscopy revealed a bladder tumor and a biopsy
specimen was obtained. Subsequently staging was performed
with contrast enhanced total body computed tomography. No
evidence of metastatic disease was found except an enlarge-
ment of an adjacent lymph node to the bladder. A radical
cystoprostatectomy was performed which revealed a 4 3 cm
mass that invaded the entire bladder wall, pericystic fat and
blood vessels as well as an adjacent lymph node (T4N1M0).
The mass cytomorphologic features demonstrated small
cells, hypercellularity, necrosis, atypical nuclear hyperchro-
matism and minimal cytoplasma (Figure 1). Immunohisto-
chemical staining was positive for CK 20, CD 56, CK 7, CK 8/
18, CEA, TTF-1, S-100, synaptophysin, chromogranin and
negative for PSA (Figures 2 and 3). Ki-67 was positive in 60%
of the neoplastic cells. It was deﬁned as a small cell
carcinoma of the urinary bladder, high grade, with neuroen-
docrine differentiaton. In light of these ﬁndings, the patient
underwent a bronchoscopy which revealed macroscopically
normal mucosa. Brushing and washing cytology samples
were analyzed with no signs of malignancy. An octeotide
scintigraphy did not identify any systemic lesions.
One month after surgery the patient was admitted to
hospital due to dysarthria, ataxia, opsoclonus, instability and
muscle weakness. On physical examination he had positive
Romberg sign, nystagmus in all directions, positive Barre sign
on his left upper extremity (LUE), decreased muscle strength
(2/5) on his right lower extremity (RLE) and a negative
Babinski sign. He was alert and orientated and had no fever.
Review of the other systems revealed no abnormality. The
patient's lab work (complete blood count, liver function tests,
electolytes, C-reactive protein, D-Dimers, partial thrombin,partial thromboplastin time, international normalized ratio)
were unremarkable. A brain MRI revealed chronic ischemic
changes. He underwent a diagnostic lumbar puncture and
cerebrospinal ﬂuid (CSF) was sent for analysis. There was mild
leukocytosis, PCR for HSV being negative. CSF cytology was
negative for malignant cells. The autoantibodies Anti-Yo and
Anti-Hu were detected in the CSF. Based on the presenting
symptoms, the work up and the ﬁndings, a neurological
consultation was ordered and a diagnosis of paraneoplastic
degenerative parencephalitis was deduced.
One month later, it was decided to administer 6 courses
of {adjuvant-likec chemotherapy with carboplatin AUC
5 day 1 and etoposide 100 mg/m2/day Days 1–3 q 21 days.
Upon completion of cycle 3 there was a signiﬁcant improve-
ment in his neurological symptoms with only a persistent
muscle weakness on his RLE (2/5) and opsoclonus. Restaging
performed with total body contrast enhanced computer
tomography revealed no signs of reccurence. An additional
three courses of carboplatin and etoposide were adminis-
tered uneventfully (Table 1).
One month after completion of his therapy the patient is
still alive with no sign of reccurence, apart from a mild
muscle weakness on his RLE (4/5).
Table 1 Patient's course.
Symptoms Physical examination Imaging Procedures Diagnosis Therapy
Admission Painless
episodes of
haematuria
Whole body
CT with IV
contrast: no
distant
metastases
Cytoscopy: bladder
tumor bronchoscopy
and octreo-scan:
within normal limits
Small cell
carcinoma of
the bladder with
neuroendocrine
differentiaton
Radical
cytoprostatectomy
1 Month
later
Dysathria
ataxia
opsoclonus
instability
muscle
weakness
Romberg sign (+), Barre
sign (+) on LUE, Babinki
sign ()muscle strength
2/5 on RLE. Alert and
oriented  3
Brain MRI:
chronic
ischemic
changes
Lumbar puncture:
(+) Anti-Hu and
Anti-Yo Ab. PCR-HSV
() Cytology
negative for
malignancy
Paraneoplastic
degenerative
parencephalitis
2 Months
later
Carboplatin AUC
5 day 1 plus
Etoposide 100
mg/m2 day 1–3
q3w
4 Months
later
Opsoclonus
muscle
weakness
Muscle strength 2/5 on
RLE
Whole body
CT with iv
contrast: no
sign of
reccurence
Completion of
3 cycles of
chemotherapy
6 Months
later
Completion of
6 cycles of
chemotherapy
7 Months
later
Muscle
weakness
Muscle strength 4/5 on
RLE
First follow up
visit
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Small cell carcinoma of the bladder is a rare, aggressive,
poorly differentiated neuroendocrine neoplasm that is
similar in clinical behavior to small cell carcinoma of the
lung. Because of its similarity to lung cancer, paraneoplastic
syndromes can arise in this setting, even though rarely.
The last 20 years the incidence of SCUC has risen signiﬁcantly
from 0.05 to 0.14 cases per 100.000 population, although a
report/publication bias cannot be excluded. They alone
account for 0.48–1% of all bladder carcinomas [2]. A past
history of smoking has been associated with the disease, men
being affected more commonly than women (4:1) and whites
more commonly than non-whites (9:1). Median age of diagnosis
is 73 years and median overall survival is 11 months, though
with varying range. Two- and ﬁve year survival is observed in
13.5% and 8% of cases. Extrapolating from SCLC, due to data
limitation in the literature, PND possibly account for less than
1% of SCUC cases [3].
Presenting symptoms are similar to other bladder tumors,
most notably gross haematuria, pelvic pain and urinary obstruc-
tion. The vast majority presented with poorly differentiated
(33%) or undifferentiated (43%) tumors. The most common sites
involved were the lateral wall (16%) or the bladder dome (10%).
Twenty-four percent of patients had distant metastases at the
time of diagnosis, and another 5% had multiple lymph node
metastases (N2 or N3) [4].The diagnosis of SCUC depends on histopathological recogni-
tion and reactivity for neuroendocrine markers such as synap-
tophysin and chromogranin-A [5]. The histological appearance
on urine cytology includes isolated single cells, hypercellularity,
nuclear moulding and nuclear hyperchromatism, with staining
for neuroendocrine markers and a haemorrhagic, necrotic
background. The typical microscopic features are characterized
by hypercellularity, necrosis, nuclear chromatin crush artefact
and mitoses. Immunohistochemical ﬁndings of SCUC include the
expression of neural markers such as NSE in 87% of patients,
chromogranin-A in only a third of cases, as well as CD44v6 and
CK20. It is also possible to ﬁnd an immunoreaction for
synaptophysin, polypeptide glycoprotein 9.5, thyroid transcrip-
tor factor-1, p53 and Ki67 [5].
No randomized clinical trials upon which to base deﬁni-
tive recommendations for the management of patients with
small cell carcinoma of the bladder exist.
For patients with localized disease and a good performance
status a combined modality approach that includes neoadjuvant
or adjuvant chemotherapy using a platinum-based regimen,
most notably carboplatin plus etoposide, coupled to cystectomy
[6,7] rather than radiotherapy which should be reserved for non
surgical candidates [8]. There are however several case series
suggesting that the neoadjuvant approach with a platinum
based c regimen may have a more favorable outcome [9].
For disseminated disease a chemotherapy regimen active
in SCLC should be administered [10,11]. Controversy remains
11A patient with NEL and PND parencephalitiswhether prophylactic cranial irradiation should be applied to
patients with limited disease or disseminated disease with a
good response [12].
Paraneoplastic neurologic syndromes are a heterogeneous
group of disorders caused by mechanisms other than
metastases, metabolic and nutritional deﬁcits, infections,
coagulopathy, or side effects of cancer treatment. These
syndromes may affect any part of the nervous system from
cerebral cortex to neuromuscular junction and muscle [13].
The pathogenesis is unclear although it is believed that an
immunologic response is directed against shared antigens
that are ectopically expressed by the tumor, but otherwise
exclusively expressed by the nervous system [14].
Well and partially characterized paraneoplastic antibodies
(Anti-Hu, Anti-Yo, Anti-Ri, Anti-Zic 4, PCA2, ANNA-3, mGlur1,
Anti-Tr, Anti-recoverinΔ, Αnti-amphiphysin, Anti-CV2) can be
detected in the serum and CSF of many, but not all, patients
with paraneoplastic syndromes and are highly suggestive of
PND [15,16]. Patients suspected of having a PND should be
examined for paraneoplastic antibodies in their serum or CSF.
These characterized paraneoplastic antibodies rarely if ever
occur in normal individuals [16,17]. Absence of these anti-
bodies does not exclude a PND, however its diagnosis requires
the absence of the metastatic and nonmetastatic complica-
tions noted earlier [17]. Imaging with MRI, PET/CTcan assist in
the diagnosis [18].
Since the majority of the PNDs are immune mediated the
general approach to therapy is removal of the antigen
source by treatment of the underlying tumor and suppres-
sion of the immune response through immunomodulation
and/or immunosuppression [19]. Prompt oncologic treat-
ment and immunotherapy may be beneﬁcial especially if
instituted during symptom progression and not later. Of
great interest is the fact that the oncologic outcome does
not differ in patients with or without a diagnosed PND [20].
4. Conclusion
In this case we had detected Anti-Hu and Anti-Yo antibodies
in the CSF of a patient with a recently resected localized
small cell carcinoma of the urinary bladder and various
neurological symptoms following surgery. Based on the
literature we administered 6 courses of etoposide and
platinum-based chemotherapy with a rapid neurological
improvement. The fact that two months after the comple-
tion of chemotherapy muscle weakness persists may be due
late-onset of chemotherapy, when the neurological deﬁcits
were already established.
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal on request.
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